Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proposed Cold MD settlement

This article was originally published in The Tan Sheet

Executive Summary

Iomedix Cold International agrees to make refunds to consumers who bought the Cold MD dietary supplement between March 26, 2004, and May 29, 2009. Consumers could receive $5 to $10 per bottle that they purchased as part of a proposed class action settlement. The settlement would resolve allegations the Mississauga, Ontario-based firm made false claims about Cold MD, according to a July 7 press release. The National Advertising Division previously ruled Iovate failed to substantiate efficacy claims (1"The Tan Sheet" April 30, 2007)

You may also be interested in...



Trial Of Cold MD Ingredients Fails To Substantiate Efficacy Claims – NAD

Iovate Health Sciences "strongly disagrees" with the National Advertising Division's recommendation to discontinue some product claims for its Cold MD dietary supplement, but said it will comply with the Council of Better Business Bureaus unit's April 20 decision

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia

Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel